Nature Communications | High-risk EBV promotes immune evasion in nasopharyngeal carcinoma by upregulating HLA-DP via BALF2-HR

This study reveals the molecular mechanism by which high-risk EBV subtypes drive immune exhaustion through the BALF2-HLA-DP-LAG-3 axis, providing a novel explanation for immunotherapy resistance in nasopharyngeal carcinoma and supporting a clinical strategy combining LAG-3 and PD-1 blockade.

 

Literature Overview

The article titled 'High-risk EBV promotes immune evasion in nasopharyngeal carcinoma by upregulating HLA-DP via the encoded BALF2-HR variant', published in Nature Communications, systematically investigates the critical role of high-risk EBV variants in immune evasion in nasopharyngeal carcinoma (NPC). The study finds that the EBV-encoded BALF2-HR variant upregulates HLA-DP expression, thereby activating the LAG-3-mediated T cell exhaustion pathway and reducing the efficacy of anti-PD-1 therapy. This mechanism provides new insights into the immune microenvironment of EBV-associated tumors.

Background Knowledge

Nasopharyngeal carcinoma (NPC) is highly prevalent in Southeast Asia and southern China, and its pathogenesis is closely linked to genetic susceptibility, environmental factors, and Epstein-Barr virus (EBV) infection. Over 95% of NPC cases are EBV-positive, indicating that EBV plays a driving role in tumorigenesis. Although PD-1 immune checkpoint inhibitors have become first-line treatments for recurrent or metastatic NPC, approximately 70% of patients do not respond, suggesting the existence of additional immune escape mechanisms. The regulatory mechanisms underlying the abnormally high expression of HLA-II molecules in NPC—and their functional roles, particularly in CD8+ T cell exhaustion—remain poorly understood. This study focuses on the high-risk EBV subtype BALF2-HR, exploring whether it influences T cell function by regulating HLA-DP, thereby contributing to immune evasion and therapy resistance, and providing a theoretical basis for developing novel combination immunotherapies.

 

 

Research Methods and Experiments

The authors analyzed 168 NPC tissue samples using Sanger sequencing and RNA-seq, validating the high prevalence of the high-risk EBV subtype BALF2-HR (C-C-T) among patients and identifying a significant positive correlation between this variant and HLA-II molecule expression—particularly HLA-DP. By constructing NPC cell lines (e.g., HK1, C666-1) with overexpression or knockout of BALF2-HR and BALF2-LR, and using flow cytometry, Western blotting, and immunofluorescence, they confirmed that BALF2-HR specifically upregulates HLA-DP expression. In a co-culture system of CD8+ T cells and NPC cells, the authors observed that BALF2-HR expression led to reduced secretion of IFN-γ, TNF, and GZMB, along with an increased proportion of PD-1+TIM-3+ exhausted T cells. Further Co-IP and mass spectrometry analyses identified that BALF2-HR specifically binds to the nuclear transport protein KPNA2, promoting the nuclear translocation of CIITA and thereby enhancing HLA-DP transcription. Although no animal models were directly used, the in vitro functional assay system closely mimics the tumor microenvironment, supporting mechanistic inference.

Key Conclusions and Perspectives

• The high-risk EBV subtype BALF2-HR significantly upregulates HLA-DP expression, a process dependent on its specific binding to KPNA2 and the nuclear translocation of CIITA—this identifies a new intervention node in the upstream regulation of HLA-DP, suitable for designing gene-targeting experiments
• HLA-DP binds to LAG-3 on the surface of CD8+ T cells, inducing T cell exhaustion and suppressing cytotoxic function—highlighting LAG-3 as a key immune checkpoint in NPC and supporting its inclusion as a combination therapy target in preclinical validation
• The efficacy of anti-PD-1 monotherapy is limited by BALF2-HR status, whereas combining anti-LAG-3 treatment can significantly restore T cell function and enhance tumor clearance—supporting testing dual immune checkpoint blockade strategies in NPC models to guide drug development
• Different HLA-DP alleles exhibit varying affinities for LAG-3, potentially influencing the degree of individual immune escape—suggesting that HLA-DP genotyping should be included in population cohort studies to explore its potential as a predictive biomarker

Research Significance and Prospects

This study establishes, for the first time, a direct link between EBV genetic variation and the HLA-DP-LAG-3 immunosuppressive axis, providing a paradigm for understanding immune escape mechanisms in virus-associated cancers. From a drug development perspective, it supports the development of LAG-3-targeting monoclonal or bispecific antibodies, particularly for BALF2-HR-positive NPC patients. In clinical monitoring, BALF2 genotyping and HLA-DP expression levels may serve as biomarkers to predict anti-PD-1 response, enabling precision immunotherapy. Moreover, this mechanism may also apply to other EBV-associated malignancies such as EBV-associated gastric cancer (EBVaGC), suggesting broader implications for research into virus-driven cancers.

 

 

Conclusion

This study reveals a complete mechanistic chain whereby high-risk EBV, through the BALF2-HR variant, upregulates HLA-DP, subsequently activating the LAG-3 pathway to induce CD8+ T cell exhaustion, thereby promoting immune evasion and resistance to anti-PD-1 therapy. This finding not only deepens our understanding of the NPC immune microenvironment but also proposes a novel therapeutic strategy combining PD-1 and LAG-3 blockade. From bench to bedside, this mechanism provides a solid foundation for patient stratification, response prediction, and the design of novel immunotherapeutic combinations. In the future, assessing BALF2 genotype and HLA-DP expression levels could guide personalized immunotherapy decisions and improve long-term survival in NPC patients. Additionally, this pathway offers a valuable molecular target for immunotherapeutic interventions in other virus-associated cancers, advancing the field of precision cancer immunology.

 

Yi Meng, Qian Wang, Lei Shi, Junshang Ge, and Wei Xiong. High-risk EBV promotes immune evasion in nasopharyngeal carcinoma by upregulating HLA-DP via the encoded BALF2-HR variant. Nature Communications.